Born: New Braunfels, Texas, USA
Place of study: University of Leeds, England
Contribution to breast cancer research:
- Dr. Jordan’s PhD program involved studying anti-estrogens.
- He studied the effects of tamoxifen and other selective estrogen receptor modulators and their effects on bone density. Tamoxifen has since then revolutionized the treatment of breast cancer.
- His research demonstrated that post-menopausal women who took these drugs had lower chances of bone erosions and elevated blood pressure.
- His recent work shows that administering estrogen at the right time destroys cancer cells rather than helping them grow.
Leeds University, Pharmacology lecturer (1974-79)
Northwestern University Medical School, Professor of Cancer Pharmacology (1993)
Lombardi Comprehensive Cancer Center, Professor of Oncology and Pharmacology
Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research (2001)
Officer of the Most Excellent Order of the British Empire (OBE) for services to international breast cancer research (2002)
Medal of Honor for basic research, American Cancer Society (2002)
Charles F. Kettering Prize (2003)
American Cancer Society Award for Chemoprevention (2006)
Gregory Pincus Memorial Award and Medal (2007)
Honorary Fellowship of the Royal Society of Medicine (2008)
Dr. Jordan is often referred to as the “father” of the anticancer drug tamoxifen.
1. (2009) V. Craig Jordan, internationally renowned breast cancer scientist, joins Georgetown’s Lombardi Comprehensive Cancer Center, Cancer Biology & Therapy, 8:8, 658-664.
2. V. Craig Jordan. Available from: https://en.wikipedia.org/wiki/V._Craig_Jordan. Accessed on 27 October 2020.
Image courtesy: https://commons.wikimedia.org/wiki/File:215692_Jordan_C_(2).jpg